MV BioTherapeutics
MV BioTherapeutics is a spin-off of the Institute for Research in Biomedicine (IRB, affiliated to USI) which was established in 2018, originally as MicroVaccines and later renamed MV BioTherapeutics. Its founder, Dr. Fabio Grassi (researcher and group leader at the IRB), has developed an innovative technology platform for the development of oral vaccines against intestinal infections, with the aim of addressing currently unresolved medical needs with high patient accessibility. In 2017, Grassi took the initial project, called EXEAD, to the then StartCup Ticino (now Boldbrain), coming in second in the finals. The startup, currently located within the IRB laboratories, holds a patent for Apy platform a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions.
